Exegenesis Bio

Exegenesis Bio is a clinical-stage global cell and gene therapy company founded in 2019, with operations in Philadelphia, Boston, China, and Singapore. The company focuses on developing innovative gene therapies targeting central nervous system, ophthalmology, and liver diseases, backed by strong financial resources and integrated manufacturing capabilities.

With a mission to transform science into cures, Exegenesis Bio aims to increase access to safe and effective one-time curative therapies for patients worldwide. Their advanced platforms, including AAVarta for capsid discovery and Constellation for DNA expression design, support their commitment to building a robust gene therapy pipeline.

Generated from the website